Stockreport

MaxCyte signs strategic platform license with Be Biopharma [Seeking Alpha]

MaxCyte, Inc.  (MXCT) 
PDF Under the terms of the agreement, Be Bio obtains non-exclusive research, clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT plat [Read more]